CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

Rhea-AI Summary

CytoDyn Inc. (OTCQB: CYDY) announced a webcast on July 22, 2021, hosted by CEO Nader Pourhassan and other executives to discuss recent clinical trial results for leronlimab, their CCR5 antagonist. The webcast will cover updates on mTNBC, COVID-19, and NASH trials, as well as the status of the BLA resubmission for HIV. Participants can submit questions online before and during the event. The archived webcast will be available for 30 days post-event.

Positive

• Webcast scheduled to discuss recent clinical trial data, potentially enhancing investor confidence.
• Updates on multiple therapeutic indications of leronlimab, indicating ongoing development.

Negative

• No new clinical trial results were announced, which may lead to investor uncertainty.

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Thursday, July 22, 2021.

Management will provide a full discussion of the results from the recently reported data from the mTNBC trials, along with updates on cancer, COVID-19, and NASH trials, and the status of the resubmission of the BLA for HIV.

Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.

Date:		Thursday, July 22, 2021
Time:		1:00 pm PT / 4:00 pm ET
Dial-In:		None

Questions:

• Prior to the webcast, questions can be submitted online to ir@cytodyn.com.
• During the webcast, questions can be submitted through the webcast link below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/46064/indexl.html

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until August 22, 2021.

CONTACTS

Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com

FAQ

What is the date of CytoDyn's upcoming investment community webcast?

The webcast is scheduled for July 22, 2021.

What topics will be covered in the CytoDyn webcast?

The webcast will cover recent mTNBC trial results, updates on COVID-19, NASH trials, and the BLA resubmission for HIV.

How can I participate in the CytoDyn webcast?

You can participate by accessing the webcast on CytoDyn's corporate website and submitting questions online.

Who will host the CytoDyn investment community webcast?

Nader Pourhassan, Ph.D., along with other executives, will host the webcast.

Where can I find the archived CytoDyn webcast?

The archived webcast will be available on CytoDyn's corporate website for 30 days after the event.